
You are here
Scheduling delegate's interim decisions and invitation for further comment: ACCS/ACMS, November 2016
Scheduling medicines and poisons
3 Summary of delegate's interim decisions
Part A - Interim decisions on matters referred to an expert advisory committee (November 2016)
3. Advisory Committee on Medicines Scheduling (ACMS #19)
Substance | Interim decision |
---|---|
Vitamin D |
Schedule 3 - Current entryVITAMIN D for human therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose. Appendix H - New EntryVITAMIN D The proposed implementation date is 1 June 2017. |
Melatonin | The delegate's interim decision is that the current scheduling for melatonin remains appropriate. |
Paracetamol compounded with caffeine |
Schedule 2 - Amend EntryPARACETAMOL for therapeutic use:
The proposed implementation date is 1 June 2017. |
Vardenafil | The delegate's interim decision is that the current scheduling of vardenafil remains appropriate. |
Cetirizine hydrochloride |
Schedule 4 - Amend EntryCETIRIZINE HYDROCHLORIDE except:
Schedule 2 - Amend EntryCETIRIZINE HYDROCHLORIDE in preparations for oral use except in preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age an over when:
The proposed implementation date is 1 June 2017. |
Tianeptine |
Schedule 4 - New EntryTIANEPTINE. Appendix D item 5 - New EntryTIANEPTINE. The proposed implementation date is 1 June 2017. |
Olaparib |
Schedule 4 - New EntryOLAPARIB. The proposed implementation date is 1 June 2017. |
Ceritinib |
Schedule 4 - New EntryCERITINIB. The proposed implementation date is 1 June 2017. |
Panobinostat lactate |
Schedule 4 - New EntryBRIVARACETAM. Appendix K - New EntryBRIVARACETAM. The proposed implementation date is 1 June 2017. |
Brivaracetam |
Schedule 4 - New EntryBRIVARACETAM. Appendix K - New EntryBRIVARACETAM. The proposed implementation date is 1 June 2017. |
Guanfacine hydrochloride |
Schedule 4 - New EntryGUANFACINE. Appendix K - New EntryGUANFACINE. The proposed implementation date is 1 June 2017. |
Follitropin delta |
Schedule 4 - New Entry#FOLLITROPIN DELTA. Appendix D, Item 1 - New EntryFOLLITROPIN DELTA (recombinant human follicle-stimulating hormone) for human use. Index - New EntryFOLLITROPIN DELTA Schedule 4 The proposed implementation date is 1 June 2017. |